Upgrade to SI Premium - Free Trial

BioAtla (BCAB)

3.66 +0.11 (3.10%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/7/26 *Est.)

Latest Headlines

Form 4 BioAtla, Inc. For: Mar 11 Filed by: Vasquez Christian June 5, 2026 4:31 PM - SEC Filing Form 4 BioAtla, Inc. For: Mar 12 Filed by: SHORT JAY M PHD June 5, 2026 4:30 PM - SEC Filing Form 4 BioAtla, Inc. For: Mar 11 Filed by: Sievers Eric June 5, 2026 4:30 PM - SEC Filing Form ARS BioAtla, Inc. For: Dec 31 June 3, 2026 4:10 PM - SEC Filing Form DEFA14A BioAtla, Inc. June 3, 2026 4:09 PM - SEC Filing Form DEF 14A BioAtla, Inc. For: Jun 03 June 3, 2026 4:07 PM - SEC Filing Context Therapeutics amends BioAtla license deal for CT-202 drug May 18, 2026 6:45 AM - StreetInsider Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 May 18, 2026 6:45 AM - Globe NewsWire Form 10-Q BioAtla, Inc. For: Mar 31 May 15, 2026 4:10 PM - SEC Filing Form 10-K/A BioAtla, Inc. For: Dec 31 April 29, 2026 4:07 PM - SEC Filing Form 8-K BioAtla, Inc. For: Apr 02 April 2, 2026 4:06 PM - SEC Filing BioAtla, Inc. (BCAB) Tops Q4 EPS by 6c March 31, 2026 5:14 PM - StreetInsider Form S-8 BioAtla, Inc. March 31, 2026 4:51 PM - SEC Filing Form 8-K BioAtla, Inc. For: Mar 31 March 31, 2026 4:07 PM - SEC Filing Form 10-K BioAtla, Inc. For: Dec 31 March 31, 2026 4:07 PM - SEC Filing BioAtla announces 50-for-1 share consolidation effective April 6 March 31, 2026 4:07 PM - StreetInsider BioAtla Announces Share Consolidation March 31, 2026 4:07 PM - Globe NewsWire BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights March 31, 2026 4:05 PM - Globe NewsWire Form 8-K BioAtla, Inc. For: Mar 17 March 23, 2026 4:04 PM - SEC Filing Form 424B2 BioAtla, Inc. March 20, 2026 4:05 PM - SEC Filing Full Article List